These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30201787)

  • 1. Immunotherapy for Prostate Cancer.
    Venturini NJ; Drake CG
    Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 30201787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
    Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
    Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
    Madan RA; Gulley JL; Kantoff PW
    Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
    Antonarakis ES
    Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunotherapy for metastatic prostate cancer: do we really need this?].
    Heidenreich A
    Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in immunotherapy for urological cancer.
    Obara W; Kato R; Kato Y; Kanehira M; Takata R
    Int J Urol; 2017 Oct; 24(10):735-742. PubMed ID: 28636222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in prostate cancer: review of the current evidence.
    Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
    Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.
    Alberti C
    G Chir; 2017; 37(5):225-235. PubMed ID: 28098061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of Prostate Cancer: Facts and Hopes.
    Bilusic M; Madan RA; Gulley JL
    Clin Cancer Res; 2017 Nov; 23(22):6764-6770. PubMed ID: 28663235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
    Comiskey MC; Dallos MC; Drake CG
    Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate Cancer Immunotherapy-Finally in From the Cold?
    Runcie KD; Dallos MC
    Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunomodulatory treatment approaches for prostate cancer].
    Reiter MA; Pfitzenmaier J; Hohenfellner M; Haferkamp A
    Urologe A; 2009 Jul; 48(7):755-63. PubMed ID: 19543879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
    Patel D; McKay R; Parsons JK
    Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for prostate cancer: what's the future?
    Arlen PM; Dahut WL; Gulley JL
    Hematol Oncol Clin North Am; 2006 Aug; 20(4):965-83, xi. PubMed ID: 16861126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising immunotherapy for prostate cancer.
    Henegan JC; Sonpavde G
    Expert Opin Biol Ther; 2018 Feb; 18(2):109-120. PubMed ID: 29231062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castrate-resistant prostate cancer: therapeutic strategies.
    Harzstark AL; Small EJ
    Expert Opin Pharmacother; 2010 Apr; 11(6):937-45. PubMed ID: 20307219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy comes of age.
    Mellman I; Coukos G; Dranoff G
    Nature; 2011 Dec; 480(7378):480-9. PubMed ID: 22193102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.